# Bristol Myers Squibb

**Source:** https://geo.sig.ai/brands/bristol-myers-squibb  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** bms.com  
**Last Updated:** 2026-04-14

## Summary

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

## Company Overview

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

BMS's diversified biopharmaceutical model addresses the pharmaceutical industry's central challenge of sustaining revenue as patent-protected blockbusters lose exclusivity: Revlimid's patent cliff (generic erosion accelerating through 2026) is being offset by the Growth Portfolio — which includes newer products with longer exclusivity runways and novel mechanisms of action that extend patent protection. The company's integrated discovery-to-commercialization model enables BMS to identify novel biological targets (particularly in immuno-oncology and targeted therapy), advance candidates through clinical development, obtain FDA approval, and deploy its global commercial infrastructure to generate peak sales from premium-priced specialty medicines. The Cobenfy acquisition represents a rare non-dopamine mechanism for schizophrenia treatment — the first new schizophrenia mechanism in decades — addressing a $10B+ market opportunity with differentiated clinical profile.

In 2025, BMS competes in global oncology, immunology, and neuroscience pharmaceuticals against Pfizer (NYSE: PFE, $58.5B 2024 revenue), AstraZeneca (NASDAQ: AZN, $54.1B 2024 revenue), and Merck (NYSE: MRK, $63.6B 2024 revenue) for oncology market share, new drug approvals, and pipeline partnership opportunities. The Karuna ($14B), Mirati ($4.8B), and RayzeBio ($4.1B) acquisitions collectively add ~$23B in pipeline value and expand BMS into three high-growth therapeutic areas: CNS/neuroscience (Cobenfy), KRAS-targeted oncology, and radiopharmaceuticals. The 2025 strategy under CEO Boerner prioritizes integrating the acquired pipelines, building commercial infrastructure for Cobenfy's schizophrenia launch, advancing the radiopharmaceutical platform from early clinical to pivotal trials, and managing the Revlimid generics headwind through continued Growth Portfolio expansion.

## Frequently Asked Questions

### What does Bristol Myers Squibb do?
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines for serious diseases. The company focuses on four key therapeutic areas: oncology (cancer), cardiovascular disease, immunology, and hematology. BMS produces blockbuster drugs including Eliquis (blood thinner), Opdivo (cancer immunotherapy), Revlimid (multiple myeloma treatment), and the recently approved Cobenfy (first novel schizophrenia treatment in 70 years).

### Who are Bristol Myers Squibb's customers and target market?
BMS serves patients worldwide suffering from serious diseases including cancer, cardiovascular conditions, autoimmune disorders, and blood diseases. The company's customers include hospitals, healthcare providers, pharmacies, and government health systems across over 100 countries. BMS develops both specialty medicines for complex conditions (like CAR-T cell therapies) and widely-prescribed treatments (like Eliquis for stroke prevention), serving millions of patients globally through partnerships with healthcare systems and payers.

### When was Bristol Myers Squibb founded?
Bristol Myers Squibb traces its heritage to two founding dates: the Squibb corporation was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers was founded in 1887 when William McLaren Bristol and John Ripley Myers purchased Clinton Pharmaceutical Company in Clinton, New York. The modern Bristol Myers Squibb was created in 1989 through the merger of these two storied pharmaceutical companies.

### Where is Bristol Myers Squibb headquartered?
Bristol Myers Squibb is headquartered in Princeton, New Jersey, at the intersection of Route 206 and Province Line Road. The company maintains major facilities across the United States including research sites in Cambridge, Massachusetts; Redwood City, California; and manufacturing in Phoenix, Arizona. Internationally, BMS operates facilities in Boudry, Switzerland; Seville, Spain; Tokyo, Japan; Bangalore, India; and many other locations worldwide.

### What is Bristol Myers Squibb's financial performance?
In 2024, Bristol Myers Squibb reported annual revenues of $48.3 billion, representing 7% growth year-over-year (9% adjusting for foreign exchange). The company's Growth Portfolio of newer products generated $22.6 billion, growing 17%. BMS has a market capitalization of approximately $106.4 billion as of late 2024. The company employs around 34,000 people globally with revenue per employee of $1.42 million.

### What makes Bristol Myers Squibb different from competitors?
BMS differentiates itself through an aggressive acquisition strategy combined with strong internal R&D, having spent over $28 billion on acquisitions in 2024 alone (Karuna, Mirati, RayzeBio). The company excels in transforming acquired assets into commercial successes, as demonstrated with Cobenfy's rapid approval. BMS has leading positions in immunotherapy (Opdivo), CAR-T cell therapy (Breyanzi, Abecma), and is pioneering radiopharmaceuticals through RayzeBio. The company's 'String of Pearls' strategy balances blockbuster drugs with innovative pipeline assets.

### Who are Bristol Myers Squibb's main competitors?
BMS's primary competitors include Pfizer (7% market share), Merck (5% market share with Keytruda competing directly against Opdivo), Johnson & Johnson (5% market share), Roche, Gilead Sciences, AstraZeneca, Novartis, and AbbVie. Merck represents the most significant competitive threat in oncology, with Keytruda generating nearly $15 billion more than Opdivo in 2024. BMS, Merck, and J&J each hold approximately 5% of the global pharmaceutical market.

### How can I contact Bristol Myers Squibb?
You can contact Bristol Myers Squibb through their main headquarters in Princeton, New Jersey. For investor relations, visit their investor website at bms.com. For career opportunities, visit careers.bms.com. For medical information or patient support, contact their medical information department through the official website at bms.com/about-us/contact-us. Media inquiries should be directed to their press relations team listed on the news and media section of their website.

### Is Bristol Myers Squibb hiring?
Yes, Bristol Myers Squibb actively recruits talent across all functional areas with over 438 positions currently available in the United States alone. The company offers 10-12 week summer internships accepting applications from August through March, as well as spring co-op positions in areas like immunology research and biologics manufacturing. Opportunities span research and development, commercial operations, manufacturing, regulatory affairs, and corporate functions. Visit careers.bms.com to explore current openings and apply.

### What's the latest news about Bristol Myers Squibb?
Recent highlights include: BMS reported Q4 2024 financial results in February 2025 showing continued revenue growth driven by Eliquis and new products; the company acquired 2seventy bio for $286 million in March 2025 to strengthen CAR-T capabilities; FDA granted accelerated approval of Breyanzi for follicular lymphoma and mantle cell lymphoma; presented positive Phase 1 data for NEX-T CAR-T therapy BMS-986353 with 94% of patients remaining off chronic immunosuppressive therapy; and extended collaboration with insitro on ALS therapies with $20 million in new funding.

### What is Bristol Myers Squibb's market position?
Bristol Myers Squibb ranks among the top 10 global pharmaceutical companies with approximately 5% market share and a market capitalization exceeding $106 billion. The company is a leader in oncology immunotherapy (though trailing Merck's Keytruda), the CAR-T cell therapy market (with Breyanzi and Abecma), and anticoagulation (with top-selling Eliquis). BMS ranks second globally in hematology/oncology revenues and is building leadership positions in radiopharmaceuticals and novel mental health treatments.

### What are Bristol Myers Squibb's future plans?
BMS is focused on transitioning from legacy blockbusters facing patent expiration (Eliquis, Opdivo, Revlimid) to its Growth Portfolio of 11 key brands including Cobenfy, Breyanzi, Abecma, Opdualag, Reblozyl, and Camzyos. The company plans continued dealmaking to strengthen its pipeline, with CEO Christopher Boerner outlining a strategy combining internal innovation with strategic acquisitions. Key focus areas include expanding CAR-T therapies, developing radiopharmaceuticals, advancing immunotherapies, and pursuing first-in-class mechanisms across oncology, cardiovascular, immunology, and neuroscience.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*